This seems to be the trend today if you keep up with the pharma news. The website shows 5 major R and D locations in the US alone. It sounds like a new business model could be in the works here, working more with investing with small biotech companies and getting away from the block buster drugs marketing model, which is not as successful as it has been in the past.
Ambien and and Allegra are two of their popular and known drugs on the market. Five billion is a big budget and if it gets cut in half, that’s a lot of people, or possibly could some of the R and D be outsourced as so many of the other drug companies have done. BD
In a visit to Health Blog HQ yesterday(from the Wall Street Journal) , Sanofi-Aventis CEO Chris Viehbacher said he may cut his company’s budget for early-stage research in half.
The basic idea: Small biotech and pharma startups must prove the value of their ideas or perish from lack of funding. That often yields more promising candidates than internal research programs at a big pharma shops like Sanofi, where bureaucratic fiefdoms may keep unworthy ideas alive.
“Part of the reason the pharma model didn’t work is we just kept throwing money at things and hoping the next blockbuster would come along,” he said.
http://blogs.wsj.com/health/2009/03/06/sanofi-aventis-ceo-looks-to-cut-research-spending/
Related Reading:
0 comments :
Post a Comment